Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared with 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCENDI trial

Stephen B. Hanauer*, William J. Sandborn, Christian Dallaire, André Archambault, Bruce Yacyshyn, Chyon Yeh, Nancy Smith-Hall

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

147 Scopus citations

Fingerprint

Dive into the research topics of 'Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared with 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCENDI trial'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

INIS